Companies:
50,244
Total Market Cap:
139210354677174.03
Global Rank
#49770
Country Rank
#6550
Market Cap
2,618
Price
0.0001
Change (%)
0.00%
Volume
1,790
Anthera Pharmaceuticals's latest marketcap:
2,618
As of 08/02/2025, Anthera Pharmaceuticals's market capitalization has reached $2,618. According to our data, Anthera Pharmaceuticals is the 49770th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2,618 |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -24,931,000 |
| Shares Out | 26.18 M |
| EPS (ttm) | -1.76 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | n/a |
Market Cap Chart
Data Updated: 08/02/2025
Anthera Pharmaceuticals's yearly market capitalization.
Anthera Pharmaceuticals has seen its market value drop from $36.24 M to $2,618 since 2014, representing a total decrease of 99.99% and an annual compound decline rate (CAGR) of 59.36%.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 08/02/2025 | $2,618 | 9969.23% | 49770 |
| 12/31/2024 | $26 | -98.52% | 48452 |
| 12/29/2023 | $1,754 | -33% | 46777 |
| 12/30/2022 | $2,618 | 9969.23% | 45034 |
| 12/31/2021 | $26 | -100% | 42999 |
| 12/31/2020 | $628,303 | -29.72% | 39762 |
| 12/31/2019 | $894,023 | 31.35% | 37047 |
| 12/31/2018 | $680,662 | -97.02% | 35643 |
| 12/29/2017 | $22.85 M | -16.09% | 34110 |
| 12/30/2016 | $27.23 M | -85.28% | 32072 |
Company Profile
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for patients with unmet medical needs.
Key Developments
- Sollpura: A non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for treating exocrine pancreatic insufficiency.
- Blisibimod: An investigational treatment for B-cell mediated autoimmune diseases, including IgA nephropathy, now in Phase II clinical trials.
Strategic Partnerships
The company has established license agreements with industry leaders, including:
- Amgen, Inc.
- Eli Lilly and Company
Company Background
Founded in 2004, Anthera Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Frequently Asked Questions
-
What is Anthera Pharmaceuticals's (OTC-ANTH) current market cap?As of 08/02/2025, Anthera Pharmaceuticals (including the parent company, if applicable) has an estimated market capitalization of $2,618 USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Anthera Pharmaceuticals (OTC-ANTH) rank globally by market cap?Anthera Pharmaceuticals global market capitalization ranking is approximately 49770 as of 08/02/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.